SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis
Mon, 6 Sep

SUVEN PHARMACEUTICALS has announced its results for the year ended March 2021. Let us have a look at the detailed performance review of the company during FY20-21.

SUVEN PHARMACEUTICALS Income Statement Analysis

  • Operating income during the year rose 21.1% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 15.1% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 43.9% in FY21 as against 46.1% in FY20.
  • Depreciation charges increased by 34.6% and finance costs decreased by 49.4% YoY, respectively.
  • Other income declined by 21.4% YoY.
  • Net profit for the year grew by 14.8% YoY.
  • Net profit margins during the year declined from 31.6% in FY20 to 30.1% in FY21.

SUVEN PHARMACEUTICALS Income Statement 2020-21

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Net Sales Rs m 8,338 10,097 21.1%
Other income Rs m 181 142 -21.4%
Total Revenues Rs m 8,519 10,240 20.2%
Gross profit Rs m 3,848 4,430 15.1%
Depreciation Rs m 235 316 34.6%
Interest Rs m 231 117 -49.4%
Profit before tax Rs m 3,563 4,139 16.2%
Tax Rs m 875 1,053 20.4%
Profit after tax Rs m 2,688 3,086 14.8%
Gross profit margin % 46.1 43.9
Effective tax rate % 24.6 25.4
Net profit margin % 31.6 30.1
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



LIVE Now: The EV Gold Rush Special Event

SUVEN PHARMACEUTICALS Balance Sheet Analysis

  • The company's current liabilities during FY21 stood at Rs 3 billion as compared to Rs 3 billion in FY20, thereby witnessing an increase of 0.5%.
  • Long-term debt down at Rs 356 million as compared to Rs 913 million during FY20, a fall of 61.0%.
  • Current assets rose 30% and stood at Rs 7 billion, while fixed assets rose 16% and stood at Rs 9 billion in FY21.
  • Overall, the total assets and liabilities for FY21 stood at Rs 16 billion as against Rs 13 billion during FY20, thereby witnessing a growth of 22%.

SUVEN PHARMACEUTICALS Balance Sheet as on March 2021

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Networth Rs m 8,448 11,808 39.8
 
Current Liabilities Rs m 3,198 3,215 0.5
Long-term Debt Rs m 913 356 -61.0
Total Liabilities Rs m 12,923 15,762 22.0
 
Current assets Rs m 5,111 6,665 30.4
Fixed Assets Rs m 7,812 9,097 16.5
Total Assets Rs m 12,923 15,762 22.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



SUVEN PHARMACEUTICALS Cash Flow Statement Analysis

  • SUVEN PHARMACEUTICALS's cash flow from operating activities (CFO) during FY21 stood at Rs 4 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY21 stood at Rs -3 billion on a YoY basis.
  • Cash flow from financial activities (CFF) during FY21 stood at Rs -766 million on a YoY basis.
  • Overall, net cash flows for the company during FY21 stood at Rs -45 million from the Rs 8 million net cash flows seen during FY20.

SUVEN PHARMACEUTICALS Cash Flow Statement 2020-21

Particulars No. of months 12 12 % Change
Year Ending Mar-20 Mar-21
Cash Flow from Operating Activities Rs m 4,069 3,834 -5.8%
Cash Flow from Investing Activities Rs m -4,134 -3,114 -
Cash Flow from Financing Activities Rs m 73 -766 -
Net Cash Flow Rs m 8 -45 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for SUVEN PHARMACEUTICALS

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 12.1, an decline from the EPS of Rs 21.1 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 524.6, stands at 43.2 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 6.8 times, while the price to sales ratio stands at 7.9 times.
  • The company's price to cash flow (P/CF) ratio stood at 39.2 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Sales per share (Unadj.) Rs 65.5 39.7
TTM Earnings per share Rs 21.1 12.1
Diluted earnings per share Rs 10.6 12.1
Price to Cash Flow x 22.8 39.2
TTM P/E ratio x 21.6 43.2
Price / Book Value ratio x 4.0 6.8
Market Cap Rs m 66,772 133,545
Dividends per share (Unadj.) Rs 5.0 2.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for SUVEN PHARMACEUTICALS

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 2.1x during FY21, from 1.6x during FY20. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 36.5x during FY21, from 16.4x during FY20. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 26.1% during FY21, from 31.8% during FY21. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 35.0% during FY21, from 40.5% during FY20. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 20.3% during FY21, from 22.6% during FY20. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Current ratio x 1.6 2.1
Debtors’ Days Days 513 370
Interest coverage x 16.4 36.5
Debt to equity ratio x 0.1 0.0
Return on assets % 22.6 20.3
Return on equity % 31.8 26.1
Return on capital employed % 40.5 35.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how SUVEN PHARMACEUTICALS has performed over the last 5 years, please visit here.

SUVEN PHARMACEUTICALS Share Price Performance

Over the last one year, SUVEN PHARMACEUTICALS share price has moved up from Rs 332.0 to Rs 524.6, registering a gain of Rs 192.6 or around 58.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 26,760.0 (up 0.0%). Over the last one year it has moved up from 18,734.2 to 26,760.0, a gain of 8,026 points (up 42.8%).

Overall, the S&P BSE SENSEX is up 49.2% over the year.

(To know more, check out historical annual results for SUVEN PHARMACEUTICALS and quarterly results for SUVEN PHARMACEUTICALS)

Equitymaster requests your view! Post a comment on "SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis". Click here!

  

Related Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles(Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK SUVEN PHARMACEUTICALS

  • Track your investment in SUVEN PHARMACEUTICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS 8-QTR ANALYSIS

COMPARE SUVEN PHARMACEUTICALS WITH

MARKET STATS